A literature review of quetiapine for generalized anxiety disorder

Pharmacotherapy

Volumn 35, Issue 2, 2015, Pages 175-188

  Kreys, Tiffany Jade M ^a   Phan, Stephanie V ^b  

^a CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

anxiety; generalized anxiety disorder; quetiapine; Seroquel

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORADRENALIN TRANSPORTER; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRIACYLGLYCEROL; DELAYED RELEASE FORMULATION; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

BINDING AFFINITY; BODY WEIGHT DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GENERALIZED ANXIETY DISORDER; GLUCOSE BLOOD LEVEL; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY (TOPIC); NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SOMNOLENCE; TRANQUILIZING ACTIVITY; XEROSTOMIA; ADOLESCENT; ADULT; AGED; ANXIETY DISORDERS; DELAYED RELEASE FORMULATION; DRUG MONITORING; MIDDLE AGED; PROCEDURES; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DRUG MONITORING; HUMANS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUETIAPINE FUMARATE; YOUNG ADULT;

EID: 84923273463     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1529     Document Type: Review

References (37)

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE,. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617-27.
2. Katzman MA,. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 2009; 23: 103-20.
3. Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2005; 35: 1747-59.
4. Culpepper L,. Generalized anxiety disorder and medical illness. J Clin Psychiatry 2009; 70 (Suppl 2): 20-4.
5. Nepon J, Belik SL, Bolton J, Sareen J,. The relationship between anxiety disorders and suicide attempts: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Depress Anxiety 2010; 27: 791-8.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association, 2013: 222-6.
7. Baldwin D, Woods R, Lawson R, Taylor D,. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 2011; 342: 1-11.
8. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 2008; 9: 248-312.
9. Scott M,. Seroquel XR (quetiapine fumarate) for major depressive disorder (MDD) or generalized anxiety disorder (GAD). United States Food and Drug Administration Psychopharmacologic Drugs Advisory Committee. April 9, 2009. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM248418.pdf. Accessed December 12, 2012.
10. Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes for the Psychopharmacologic Drugs Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM198219.pdf. Accessed December 12, 2012.
11. Seroquel and Seroquel XR (quetiapine fumarate) pediatric post-marketing drug utilization review. December 2011.
12. Zhornitsky S, Potvin S, Moteshafi H, Dubreucq S, Rompre PP, Stip E,. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol 2011; 26: 183-92.
13. Baune BT,. New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine. Neuropsychiatr Dis Treat 2008; 4: 1181-91.
14. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL,. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008; 33: 2303-12.
15. Buspar [buspirone hydrochloride]: prescribing information. St. Leonards, NSW, Australia: Aspen Pharma Pty Ltd; 2010.
16. Seroquel (quetiapine tablets): US prescribing information. Delaware, NY: AstraZeneca Pharmaceuticals LP; 2013.
17. Seroquel XR (quetiapine extended-release tablets): US prescribing information. Delaware, NY: AstraZeneca Pharmaceuticals LP; 2013.
18. Figueroa C, Brecher M, Hamer-Maansson J, Winter H,. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol 2009; 33: 199-204.
19. Moller H, Johnson S, Mateva T, et al. Evaluation of the feasibility of switching from quetiapine immediate release to quetiapine extended release in stable outpatients with schizophrenia. Int Clin Psychopharmacol 2008; 23: 95-105.
20. Galynker I, Khan A, Grebchenko Y, et al. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry 2005; 66: 544.
21. Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010; 13: 305-20.
22. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H,. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 2011; 31: 418-28.
23. Merideth C, Cutler AJ, She F, Eriksson H,. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol 2012; 27: 40-54.
24. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H,. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol 2010; 26: 11-24.
25. Katzman MA, Vermani M, Jacobs L, et al. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord 2008; 22: 1480-6.
26. Gabriel A,. The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): an open label naturalistic study. Clin Ter 2011; 162: 113-8.
27. Simon NM, Connor KM, LeBeau RT, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology 2008; 197: 675-81.
28. Altamura AC, Serati M, Buoli M, Dell'Osso B,. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol 2011; 26: 201-5. 20.
29. Khan A, Atkinson S, Mezhebovsky I, She F, Leathers T, Pathak S,. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study. Ann Clin Psychiatry 2013; 25: E7-22.
30. Pollack MH,. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry 2001; 62 (Suppl 19): 20-5.
31. Stein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H,. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol 2011; 26: 614-28.
32. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005; 50: 703-14.
33. Trollor JN, Chen X, Sachdev PS,. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23: 477-92.
34. Newcomer JW,. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl 1): 1-93.
35. Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011; 72: 1063-71.
36. Wang Z, Kemp DE, Chan PK, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol 2011; 14: 131-42.
37. Hoffman EJ, Mathew SJ,. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med 2008; 75: 248-62.